ТИРОНЕТ – все о щитовидной железе Для специалистов Журнал Тиронет Архив журнала 2004 год № 1-2

Современные принципы оценки уровня тиреоглобулина при наблюдении пациентов с высокодифференцированным раком щитовидной железы

К.Э. Спенсер (C.A. Spenser)
Профессор медицинского факультета университета Южной Каролины

ЛИТЕРАТУРА

1. Schulz R., Bethauser H., Stempka L., et al. Evidence for immunological differences between circulating and tissue-derived thyroglobulin in men. // Eur J Clin Invest — 1989 — Vol. 19 — P. 459 — 463.
2. Di Jesu B., Pereira R., Consiglio E., et al. Demonstration of a Ca2+ requirement for thyroglobulin dimerization and export to the golgi complex. // Eur J Biochem — 1998 — Vol. 252. — P. 583 — 590.
3. Demers L.M., Spencer C.A. Laboratory Medicine Practice Guidelines: Laboratory Support for the Diagnosis and Monitoring of Thyroid Disease. // Thyroid — 2003 — Vol. 13. — P. 57 — 67.
4. Spencer C.A., Takeuchi M., Kazarosyan M. Current Status and Performance Goals for Serum Thyroglobulin Assays. // Clin Chem — 1996 — Vol. 42. — P. 164 — 173.
5. Pacini F., Mariotti S., Formica N., Elisei R. Thyroid autoantibodies in thyroid cancer: Incidence and relationship with tumor outcome. // Acta Endocrinol — 1988 — Vol. 119. — P. 373 - 380.
6. Rubello D., Casara D., Girelli M.E., et al. Clinical meaning of circulating antithyroglobulin antibodies in differentiated thyroid cancer: a prospective study. // J Nucl Med — 1992 — Vol. 33. — P. 1478 — 1480.
7. Spencer C.A., Wang C., Fatemi S., et al. Serum Thyroglobulin Autoantibodies: Prevalence, influence on serum thyroglobulin measurement and prognostic significance in patients with differentiated thyroid carcinoma. // J Clin Endocrinol Metab — 1998 — Vol. 83 — P. 1121 — 1127.
8. Feldt-Rasmussen U., Petersen P.H., Blaabjerg O., Horder M. Long-term variability in serum thyroglobulin and thyroid related hormones in healthy subjects. // Acta Endocrinol (Copenh) — 1980 — Vol. 95. — P. 328 — 334.
9. Feldt-Rasmussen U., Schlumberger M. European interlaboratory comparison of serum thyroglobulin measurement. // J Endocrinol Invest — 1988 — Vol. 11. — P. 175 — 181.
10. Feldt-Rasmussen U., Profilis C., Colinet E., et al. Human thyroglobulin reference material (CRM 457) 2^nd part: Physicochemical characterization and certification. // Ann Biol Clin — 1996 — Vol. 54. — P. 343 — 348.
11. Mazzaferri E.L., Jiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. // Am J Med — 1994 — Vol. 97. — P. 418 — 428.
12. Schlumberger M., Travagli J.P., Fragu P., et al. Follow-up of patients with differentiated thyroid carcinoma. Experience at Institut Gustave-Roussy, Villejuif. // Eur J Cancer Clin Oncol — 1988 — Vol. 24. — P. 345 — 350.
13. Torrens J.I., Burch H.B. Serum thyroglobulin measurement. Utility in clinical practice. // Endocrinol Metab Clin N Amer — 2001 — Vol. 30. — P. 429 - 467.
14. Rodbard D. Statistical estimation of the minimal detectable concentration ("sensitivity") for radioligand assays. // Anal Biochem — 1978 — Vol. 90. — P. 1 — 12.
15. Spencer C.A., Takeuchi M., Kazarosyan M. Current status and performance goals for serum thyrotropin (TSH) assays. // Clinical Chemistry — 1996 — Vol. 42. — P. 141 — 145.
16. Vogeser M., Weigand M., Fraunberger P., et al. Evaluation of the ADVIA Centaur TSH-3 assay. // Clin Chem Lab Med — 2000 — Vol. 38. — P. 331 — 334.
17. Fatemi S., Delaney M., Guttler R., et al. The First-Year Post-Thyroidectomy Serum Tg Concentration (During LT4 Treatment) Predicts Long-Term Recurrence Risk in Patients with Papillary Thyroid Carcinoma (PTC). // J Clin Endocrinol Metab — 2004 (manuscript in preparation).
18. Saboori A.M., Rose N.R., Kuppers R.C., et al. Immunoreactivity of multiple molecular forms of human thyroglobulin. // Clin Immunol Immunopathol 1994 — Vol. 72. — P. 121 — 128.
19. Sugawa H., Smith E., Imura H., Mori T. A thyroid cancer specific monoclonal antibody which recognizes cryptic epitope(s) of human thyroglobulin. // Mol Cell Endocrinol — 1993 — Vol. 93. — P. 207 — 211.
20. Fatemi S., Nicoloff J., LoPresti J., et al. Clinical significance of serial serum Tg autoantibody (TgAb) patterns in patients with differentiated thyroid cancers (DTC). // 12th. International Congress of Thyroidology — 2000, Kyoto.
21. Franke W.G., Zophel K., Wunderlich G.R., et al. Thyroperoxidase: a tumor marker for post-therapeutic follow-up of differentiated thyroid carcinomas? Results of a time course study. // Cancer Detect Prev — 2000 — Vol. 24. — P. 524 — 530.
22. Massart C., Maugendre D. Importance of the detection method for thyroglobulin antibodies for the validity of thyroglobulin measurements in sera from patients with Graves' disease. // Clin Chem — 2002 — Vol. 48. — P. 102 — 107.
23. Spencer CA. Recoveries cannot be used to authenticate thyroglobulin (Tg) measurements when sera contain Tg autoantibodies. // Clin Chem - 1996 — Vol. 42. — P. 661 — 663.
24. Mariotti S., Barbesino G., Caturegli P., et al. Assay of thyroglobulin in serum with thyroglobulin autoantibodies: an unobtainable goal? // J Clin Endocrinol Metab — 1995 — Vol. 80. — P. 468 — 472.
25. Levinson S.S. The nature of heterophilic antibodies and their role in immunoassay interference. // J Clin Immunoassay — 1992 — Vol. 15. — P. 108 — 115.
26. Preissner C.M., O'Kane D.J., Singh R.J., et al. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. // J Clin Endocrinol Metab — 2003 — Vol. 88. — P. 3069 — 3074.
27. Benvenga S., Burek C.L., Talor M., et al. Heterogeneity of the thyroglobulin epitopes associated with circulating thyroid hormone autoantibodies in Hashimoto's thyroiditis and non-autoimmune thyroid diseases. // J Endocrinol Invest — 2002 — Vol. 25. — P. 977 — 982.
28. Schneider A.B., Pervos R. Radioimmunoassay of human thyroglobulin: effect of antithyroglobulin autoantibodies. // J Clin Endocrinol Metab — 1978 — Vol. 47. — P. 126 — 137.
29. Feldt-Rasmussen U., Rasmussen A. Serum thyroglobulin (Tg) in presence of thyroglobulin autoantibodies (TgAb). Clinical and methodological relevance of the interaction between Tg and TgAb in vitro and in vivo. // J Endocrinol Invest — 1985 — Vol. 8. — P. 571 — 576.
30. Pacini F., Agate L., Elisei R., et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131I whole body scan: Comparison of patients treated with high 131I activities versus untreated patients. // J Clin Endocrinol Metab — 2001 — Vol. 86. — P. 4092 — 4097.
31. Koh J.M., Kim E.S., Ryu J.S., et al. Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study. // Clin Endocrinol - 2003 - Vol. 58. — P. 421 — 427.
32. Hollowell J.G., Staehling N.W., Hannon W.H., et al. Serum thyrotropin, thyroxine, and thyroid antibodies in the United States population (1988 to 1994): NHANES III. // J Clin Endocrinol Metab — 2002 — Vol. 87. — P. 489 — 499.
33. Bachelot A., Cailleuz A.F., Klain M., et al. Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. // Thyroid — 2002 — Vol. 12. — P. 707 — 711.
34. Gardner D.F., Rothman J., Utiger R. Serum thyroglobulin in normal subjects and patients with hyperthyroidism due to Graves' disease: effects of T3, iodide, 131I and antithyroid drugs. // Clin Endocrinol — 1979 — Vol. 11. — P. 585 — 594.
35. Ozata M., Suzuki S., Miyamoto T., et al. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. // J Clin Endocrinol Metab — 1994 — Vol. 79. — P. 98 — 105.
36. Savelli G., Chiti A., Rodari M., et al. Predictive value of thyroglobulin changes for the efficacy of thyroid remnant ablation. // Tumori — 2001 — Vol. 87. — P. 42 — 46.
37. Antonelli A., Miccoli P., Fallahi P., et al. Role of neck ultrasonography in the follow-up of children operated on for papillary cancer. // Thyroid - 2003 — Vol. 13. — P. 479 — 484.
38. Mazzaferri E.L., Robbins R.J., Spencer C.A., et al. A consensus report on the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. // J Clin Endocrinol Metab — 2003 — Vol. 88. — P. 1433 — 1441.
39. Torlontano M., Crocetti U., D'Aloiso L., et al. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. // Eur J Endocrinol — 2003 — Vol. 148. — P. 19 — 24.
40. Hocevar M., Auersperg M. Role of serum thyroglobulin in the pre-operative evaluation of follicular thyroid tumors. // Eur J Surg Oncol — 1998 — Vol. 24. — P. 553 — 557.
41. Ericson U.B., Tegler L., Lennquist S., et al. Serum thyroglobulin in differentiated thyroid carcinoma. // Acta Chir Scand — 1984 — Vol. 150. — P. 367 — 375.
42. Bayraktar M., Ergin M., Boyacioglu A., Demir S. A preliminary report of thyroglobulin release after fine needle aspiration biopsy of thyroid nodules. // 18 J Int Med Res — 1990 — P. 253 — 255.
43. Haugen B.R., Pacini F., Reiners C., et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. // J Clin Endocrinol Metab — 1999 — Vol. 84. — P. 3877 — 3885.
44. Spencer C.A., LoPresti J.S., Fatemi S., Nicoloff J.T. Detection of residual and recurrent differentiated thyroid carcinoma by serum Thyroglobulin measurement. // Thyroid — 1999 — Vol. 9. — P. 435 — 441.
45. Schlumberger M., Fragu P., Lumbroso J., et al. Circulating thyrotropin and thyroid hormones in patients with metastases of differentiated thyroid carcinoma: relationship to serum thyrotropin levels. // J Clin Endocrinol Metab - 1980 — Vol. 51. — P. 513 — 519.
46. Spencer C., Fatemi S. Thyroglobulin Measurements in Thyroid Cancer Evaluation and Surveillance. In Current Concepts in Thyroid Disorders and Pathogenesis and Treatment of Thyroid Neoplasms. 2004; Editor: Bryan Haugen. Elsevier Sciences, New York.
47. Spencer C.A., Wang C.C. Thyroglobulin measurement: Techniques, clinical benefits and pitfalls. // Endocrinol Metab Clin N Amer - 1995 — Vol. 24. -0 P. 841 — 863.